• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Leukemia, Myelomonocytic, Acute

Leukemia, Myelomonocytic, Acute - 3 Studies Found

Completed : Study of XIAP Antisense Given With Chemotherapy for Refractory/Relapsed AML
: Leukemia, Myelomonocytic, Acute
: 2006-08-10
: Drug: XIAP antisense 2 days loading dose followed by weekly 2hr infusion
Completed : Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia
: Leukemia, Myelomonocytic, Acute
: 2010-07-30
: Drug: Erlotinib Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle wil
Active, not recruiting : A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
: Myelomonocytic Leukemia
: 2013-01-24
: Drug: Ruxolitinib In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.